SCHEMBL4076569

SCHEMBL4076569

OC[C@H](Nc1nc(Nc2cc(C3CC3)[nH]n2)c2ccsc2n1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 10/20 0.65
IGF1R P08069 8/20 0.54
DYRK3 O43781 1/20 0.51
JAK2 O60674 1/20 0.51
PRKD3 O94806 1/20 0.51
MAP4K4 O95819 1/20 0.51
PAK4 O96013 1/20 0.51
ABL1 P00519 1/20 0.51
LCK P06239 1/20 0.51
FYN P06241 1/20 0.51
CSF1R P07333 1/20 0.51
RET P07949 1/20 0.51
MET P08581 1/20 0.51
ROS1 P08922 1/20 0.51
FGFR1 P11362 1/20 0.51
PRKACA P17612 1/20 0.51
FLT1 P17948 1/20 0.51
FGFR3 P22607 1/20 0.51
KDR P35968 1/20 0.51
SYK P43405 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4151812 0.86 NTRK1 (0.70) NTRK1IGF1RPAK4GSK3BULK1
SCHEMBL4066282 0.86 IGF1R (0.71) NTRK1IGF1RDYRK3JAK2PRKD3
SCHEMBL4160193 0.84 NTRK1 (0.65) NTRK1IGF1RDYRK3JAK2PRKD3
SCHEMBL4551106 0.84 NTRK1 (0.65) NTRK1IGF1RDYRK3JAK2PRKD3
SCHEMBL4074253 0.84 NTRK1 (0.73) NTRK1IGF1RPAK4ULK1
SCHEMBL4155683 0.82 NTRK1 (0.65) NTRK1IGF1RPAK4GSK3B
SCHEMBL4155715 0.82 NTRK1 (0.68) NTRK1IGF1RULK1
SCHEMBL4075190 0.82 NTRK1 (0.65) NTRK1IGF1RPAK4GSK3B
SCHEMBL27654586 0.81 NTRK1 (0.64) NTRK1IGF1RPAK4ULK1
SCHEMBL4074989 0.81 NTRK1 (0.64) NTRK1IGF1RPAK4ULK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1686999-B1 PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES ASTRAZENECA AB (SE) 2009-07-01 EP disclosed
US-20090005396-A1 Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain ASTRAZENECA AB (SE) 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005396-A1 Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain P2RX3, DPYD, TYMP NTRK1 3656/4885IGF1R 4775/4885DYRK3 2793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.